November 20, 2025. Leads & Copy — Maxwell Biosciences has appointed Dr. Brad Wenstrup, a biodefense expert, to its Board of Directors, according to a recent announcement.
Dr. Wenstrup is a retired Army Colonel with a distinguished record of government, military and medical service, including over 27 years in private practice and 25 years in military medicine and surgery. He has expertise in managing bacterial, fungal and viral infections, served as the Chief of Surgery with the 344th Combat Support Hospital in Iraq, and held positions at Walter Reed National Military Medical Center and as Medical Policy Advisor to the Chief of the Army Reserve.
Scotch McClure, CEO, Founder & Chairman of Maxwell Biosciences, stated that Dr. Wenstrup has spent over 20 years battling for better healthcare for citizens and putting America first. McClure also said he looks forward to working with Dr. Wenstrup to help Congress and the executive branch understand the global security impact of Maxwell’s anti-infective therapeutics platform.
Dr. Wenstrup has collaborated with agencies such as DARPA, DTRA, BARDA, NCMI, HHS, NIH, FDA, NIAID, CMS, VA and Military Health. He also served on the Cincinnati Board of Health from 2010 to 2012.
From 2013 to 2025, Dr. Wenstrup represented Ohio’s 2nd District in the U.S. House of Representatives, serving on committees such as Armed Services, Veterans Affairs, Ways and Means and the Permanent Select Committee on Intelligence, where he held multiple Chairmanships. As a leader on the Intelligence Committee, Dr. Wenstrup played a pivotal role in biodefense and was selected as Chairman of the Select Subcommittee on the Coronavirus Pandemic. He currently serves on the President’s Intelligence Advisory Board.
Maxwell Biosciences is a global health technology company that develops immune-inspired small molecules called Claromers®. These molecules mimic and enhance the body’s natural defenses, destroying pathogenic bacteria, viruses, fungi and biofilms without harming healthy cells or the microbiome.
Originally developed for critical infectious diseases, Maxwell’s technology is being commercially deployed across cosmetics, personal care, medical coatings and biodefense. Claromers® require no refrigeration and are stable in harsh environments.
Maxwell Biosciences has active collaborative agreements with the U.S. military and governments worldwide, with FDA clinical trials planned for 2026. Non-pharmaceutical commercialization is underway with pilot access for select partners.
Maxwell’s AI-first platform enables rapid innovation against resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions.
Dr. Wenstrup expressed his excitement about joining Maxwell Biosciences, citing the opportunity to enhance the health of people worldwide.
Contact:
Media
press@maxwellbiosciences.com
Investors
investor.relations@maxwellbiosciences.com
Source: Maxwell Biosciences
